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Background and purpose: Much interest is currently being focused on the 
antinociceptive effects mediated by nicotinic acetylcholine (nACh) receptors, 
including their location and mechanism of action. The purpose of this study is to 
elucidate these issues using 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine (5IA), a 
nACh receptor agonist, and [
125
I]5IA. 
Experimental approach: We partially ligated the sciatic nerve of a SD rat to induce 
neuropathic pain (Seltzer’s PSL model). We then examined the changes in central 
nACh receptor density in the model using [
125
I]5IA autoradiography and the 
involvement of nACh receptors in antinociceptive effects in the region where changes 
occurred. 
Key results: Autoradiographic studies showed that the accumulation of [
125
I]5IA and 
the number of nACh receptors in the thalamus of PSL rats were increased about 
2-fold compared to those in the sham-operated rats. No change was observed in other 
regions. This is the first report of the upregulation of thalamic nACh receptors under 
chronic painful conditions. Thus, we investigated the action site of 5IA in the 
thalamus. Rats receiving an intra-ventral posterolateral thalamic nucleus (VPL) 
administration of 5IA demonstrated a significant and dose-dependent antiallodynic 
effect. This effect was completely antagonized by coadministered mecamylamine. 
The blockade of nACh receptors in the VPL by mecamylamine caused a 70% 
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decrease in the antiallodynic effect of i.c.v. administered 5IA. Moreover, intra-VPL 
administered mecamylamine induced significant hyperalgesia.  
Conclusions and implications: The findings in the present study suggest that the 
nACh receptors expressed in the VPL play an important role in the antiallodynic 
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Numerous studies have shown that nicotinic acetylcholine (nACh) receptor 
agonists possess analgesic effects (Decker et al., 2004; Jain, 2004). Because these 
effects are not antagonized by opioid antagonists and arise from the activation of 
nACh receptors (Bannon et al., 1998a), much interest has been focused on nACh 
receptors as a novel target of antinociceptive drugs that do not involve the opioid 
system. Although morphine is a very well known and effective analgesic, its 
usefulness for patients with neuropathic pain is limited (Bannon et al., 1998c; 
Sindrup and Jensen, 1999). In contrast, nACh receptor agonists are able to ameliorate 
neuropathic pain by affecting systems other than the opioids (Bannon et al., 1998b; 
Bannon et al., 1998c; Decker et al., 1998). Therefore, identification of the sites of 
action of nACh receptor agonists and the elucidation of their antiallodynic 
mechanisms are desirable. 
One of the most studied nACh receptor-acting analgesics is ABT-594. It is a 
selective and potent agonist with high affinity for α4β2-nACh receptors (predominant 
in the brain), low affinity for α7-nACh receptors, and no affinity for α1β1γδ-nACh 
receptors (Donnelly-Roberts et al., 1998; Holladay et al., 1998). By virtue of this 
selectivity, ABT-594 has analgesic efficacy with an improved therapeutic window 
compared to non-selective agonists such as epibatidine (Bannon et al., 1998b).  
Recently, 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine (5-iodo-A-85380, 5IA), 
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an analogue of ABT-594, was synthesized (Saji et al., 2002). It is also an α4β2-nACh 
receptor-specific agonist (Ueda et al., 2008) with a relatively good safety profile 
(Ueda et al., 2004; Vaupel et al., 2003). In addition, radiolabeled 5IA, [
123/125
I]5IA, 
was also developed (Saji et al., 2002) and was reported to be a promising ligand for 
imaging nACh receptors in rodents and in humans (Brasic et al., 2009; Mamede et al., 
2004; Mamede et al., 2007; Oishi et al., 2007; Saji et al., 2002). Nonradioactive 5IA 
and [
123/125
I]5IA can be considered the same compound with regard to their 
biodistribution or metabolism. Therefore, the pharmacokinetics, receptor occupancy, 
and binding potential (an index of nACh receptor density) of 5IA are able to be 
measured readily using [
123/125
I]5IA. Studies using 5IA have the advantage that 
pharmacodynamic effects can be compared directly with the pharmacokinetic profile 
of the compound. 
Previous studies have demonstrated the upregulation of spinal muscarinic 
acetylcholine receptors (Chen and Pan, 2003) and thalamic cannabinoid CB1 
receptors (Siegling et al., 2001) in neuropathic pain models. It has been reported that 
the upregulation of muscarinic and CB1 receptors contributes to the increased 
analgesic efficacy of each agonist. Since nACh receptor agonists are also effective 
against neuropathic pain, upregulation of nACh receptors may also occur in the 
models. We hypothesized that brain regions where changes in the density or function 
of nACh receptors occurred would play an important role in antinociceptive effects, 
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provided that such changes were found under neuropathic conditions. In the present 
study we used a partial sciatic nerve ligation (PSL) model of neuropathic pain 
(Seltzer et al., 1990) and examined the changes in nACh receptors in the PSL rats 
using [
125
I]5IA. Furthermore, based on the result, we investigated the involvement of 






Animal experiments were conducted in accordance with our institutional 
guidelines, and the experimental procedures were approved by the Kyoto University 
Animal Care Committee. 
Male Sprague-Dawley rats weighing 200–250 g were purchased from Japan 
SLC Co., Ltd. (Hamamatsu, Japan). The rats were kept at a constant ambient 
temperature under a 12-hr light/dark cycle with free access to food and water. 
 
Reagents and nomenclature 
 5IA and [
125
I]5IA were synthesized according to a previously published 
method (Saji et al., 2002). Mecamylamine hydrochloride, a nACh receptor antagonist, 
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was purchased from Sigma-Aldrich (St. Louis, MO). All drugs were administered in 
physiological saline solution. All other chemicals used were of reagent grade. 
The nomenclature for receptors follows the guide to receptors and channels 
(Alexander et al., 2008). 
 
Surgical operation 
PSL neuropathic pain was established according to a previously published 
method (Seltzer et al., 1990). Under sodium pentobarbital (50 mg·kg
-1
, i.p.) 
anesthesia, the right sciatic nerve was exposed just distal to the branch leading to the 
posterior biceps femoris/semitendinosus muscles. A 7-0 silk suture was inserted into 
the nerve and tightly ligated so that the dorsal 1/3 to 1/2 of the nerve was trapped in 
the ligature. In the sham-operated rats, the sciatic nerve was exposed, but was left 
intact. 
After recovery from the surgery, the rats were implanted with stainless steel 
guide cannulae (o.d. 0.7 mm, i.d. 0.38 mm) under sodium pentobarbital (50 mg·kg
-1
, 
i.p.) anesthesia for i.c.v. or intra-ventral posterolateral thalamic nucleus (VPL) 
administration. The rats were placed into a stereotaxic apparatus (SR-5, Narishige Co., 
Ltd., Tokyo, Japan) and unilaterally implanted with a guide cannula above the lateral 
ventricle (0.8 mm posterior and 1.5 mm lateral to bregma, 2.0 mm below the outer 
surface of the skull) for i.c.v. administration or above the left VPL, which was 
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contralateral to the nerve ligation (2.4 mm posterior and 3.3 mm lateral to bregma, 
2.0 mm below the outer surface of the skull) for intra-VPL administration. The 
stereotaxic coordinates were determined following an atlas (Paxinos and Watson, 
2005). The guide cannulae were held firmly in place using dental acrylic cement. 
After surgery, the rats were individually returned to their cages and left to recover for 
5 days or more until the experiments. 
 
von Frey Filament Test 
Just before and two weeks after the PSL, tactile sensitivity was measured by 
the up-down method using calibrated von Frey filaments ranging from 0.07–26 g 
(North Coast Medical, Morgan Hill, CA), in a previously described method with 
slight modifications (Marcil et al., 2006). Briefly, for testing, the rats were 
individually placed on an elevated wire mesh floor. After a habituation period of 
15–30 min, the tactile stimulus was applied to the middle plantar of the each paw by 
placing the von Frey filament perpendicular to the surface of the paw. The filament 
was held in this position with enough force to cause slight bending. Each trial 
involved 10 applications of filaments every 1 to 2 s. The threshold was determined as 
the filament of the lowest stiffness at which the rat responded (quick paw flick) in 
one or more of the trial. The rats that showed a lower threshold postoperatively than 
preoperatively in both paws were considered as demonstrating allodynia and were 
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used in the following studies. 
 
Effect of 5IA and/or mecamylamine on tactile allodynia 
For i.c.v. administration, an injection cannula (o.d. 0.35 mm, i.d. 0.18 mm) 
was inserted 5.0 mm below the surface of the skull along the guide cannula. Then, 
various concentrations of 5IA (1–10 nmol/5 μL) or vehicle were infused at 5 μL/rat 
with a constant rate of 10 μL·min-1 using a microsyringe pump (EP-60; Eicom 
Corporation, Kyoto, Japan). The cannula was retained in place for an additional 1 min 
to prevent backflow of the drugs. When required, mecamylamine (5 mg·kg
-1
) was 
injected subcutaneously 30 min before i.c.v. administration of 5IA.  
For intra-VPL administration, an injection cannula was inserted 6.2 mm 
below the surface of the skull. Subsequently, vehicle, 5IA (1–50 nmol/0.5 μL), 
mecamylamine (1–10 nmol/0.5 μL), or a mixed solution of 5IA and mecamylamine 
(10 nmol each/0.5 μL) was infused at 0.5 μL/rat with a constant rate of 0.4 μL·min-1. 
The cannula was retained in place for an additional 1 min. 
For double injection, the cannula for intra-VPL administration was inserted 
intra-VPL, and mecamylamine (10 nmol/0.5 μL) or vehicle was infused in the same 
way as described above. Five minutes later, the cannula for i.c.v. administration was 
inserted, and 5IA (10 nmol/5 μL) or vehicle was infused as described above. Both 
cannulae were retained in place for an additional 1 min. 
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 Just before and 15, 30, 60, 90, and 120 min after administration, tactile 
allodynia was evaluated using the von Frey filament test. The results were expressed 




Post-drug threshold - Pre-drug threshold




Inclined plane test 
The inclined plane test was carried out using a sliding apparatus (Medical 
Agent Co., Ltd., Kyoto, Japan), as described previously (Okada et al., 2002). This 
procedure was used to evaluate the effects of antiallodynic drugs on motor function 
(Fukui et al., 2001; Okada et al., 2002; Yasuda et al., 2005). It was previously 
reported that intraperitoneal administration of baclofen, which causes muscle 
relaxation, significantly reduced the slope angle, thus indicating the appropriateness 
of this procedure (Fukui et al., 2001). Each rat was placed on a stainless steel plate 
inclined at 30°, and the angle of the plate was increased at a rate of 2°·s
-1
. The 
maximum angle of the plane at which the rat maintained its body position without 
sliding down was determined.  
The rats were habituated to the procedure three times per day. After two days 
of habituation, the test was performed three times, and the mean of the last two values 
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was taken as a control. Soon after measuring the control value, drugs or vehicle were 
administered via each route as described in the section entitled Effect of 5IA and/or 
mecamylamine on tactile allodynia, and the maximum angle before sliding down was 
determined at 15, 30, 60, 90, and 120 min after administration. Drugs were used at 
the maximum concentration for each administration route. The data are represented as 
a percentage of the control value. 
 
Ex vivo autoradiography 
Ex vivo autoradiography was performed using a previously described method 
(Kanegawa et al., 2006) with slight modifications. Three groups of rats, a 
sham-operated group, a 2 week, and a 1 month post-PSL group, were used in this 
experiment. Each group consisted of 4 to 7 animals. 
Each rat was injected with 2 MBq of [
125
I]5IA via its tail vein and sacrificed 
60 min after radioligand injection. Their brains were quickly removed, frozen in 
hexane (–80°C), and cut into 20 μm-thick coronal sections with a cryomicrotome 
(CM3000, Leica, Germany). The sections were exposed to imaging plates (BAS-UR, 
Fuji Photo Film Co., Ltd., Tokyo, Japan) with 
125
I autoradiographic microscale 
standards (Amersham Biosciences, Buckinghamshire, UK). After 25 hr exposure, the 
[
125
I]5IA autoradiograms were obtained using a bioimaging analyzer (BAS 3000, Fuji 
Photo Film Co., Ltd.), and quantitative densitometric analyses were performed with 
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dedicated software (Image Gauge ver. 3.1, Fuji Photo Film Co., Ltd.). Regions of 
interest (ROIs) were drawn over eight brain regions bilaterally (frontal cortex, 
striatum, hippocampus, thalamus, pedunculopontine tegmental nucleus (PPTg), 
nucleus raphe magnus (NRM), locus coeruleus, and cerebellum). Data were 
represented as the mean of the ligated and contralateral side. 
 
In vitro autoradiography 
Three groups of rats were used as described for the ex vivo autoradiography. 
Each group consisted of 5 to 7 animals. The rats were sacrificed, and their brains 
were removed and frozen immediately. Each frozen brain was cut into 20 μm-thick 
coronal sections, thaw-mounted onto gelatin-coated glass slides, and kept frozen at – 
80°C until use. 
A method for the autoradiographic determination of receptor density was 
previously published (Suzdak et al., 1994; Tanaka et al., 1993). A binding assay was 
conducted using a modification of a previously described method (Mukhin et al., 
2000). The assay buffer used was 50 mM Tris-HCl (pH 7.0) containing 120 mM 
NaCl, 5 mM KCl, 2.5 mM CaCl2, and 1 mM MgCl2. The sections were incubated 
with 23.75 to 380 pM [
125
I]5IA (specific activity: 220 Ci·mmol
-1
) in the same buffer 
for 1 hr at 25°C, then rinsed twice in ice-cold buffer for 5 min each time, and once in 
distilled water for 1 min, and dried under a cold air stream. Nonspecific binding was 
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determined in the presence of 300 μM (–)-nicotine. The sections were exposed to the 
imaging plates with 
125
I standards for 20 hr. The autoradiograms were obtained and 
the quantitative analyses were performed in a similar way to that described above. 
Values for the maximum density of binding sites (Bmax) were gained from saturation 
binding isotherms (one-site binding) of specific binding by means of nonlinear curve 
fitting (Prism 5.00, GraphPad Software, San Diego, CA). 
 
Statistical Analyses 
 After the behavioral experiments, the rats were sacrificed, and their brains 
were removed and frozen immediately. Coronal sections (20 μm) including the VPL 
were prepared and thaw-mounted onto gelatin-coated glass slides and subjected to 
Nissl staining. The placements of the tips of the injection cannulae were confirmed by 
using the atlas (Paxinos and Watson, 2005). Only data from rats with the injection 
cannulae correctly placed in the VPL were used for the statistical analyses. 
The analyses of the data from the von Frey filament test and the inclined 
plane test were performed using two-way analysis of variance (ANOVA) with 
repeated measures. If there was a significant difference, a post hoc one-way ANOVA 
followed by a Tukey-Kramer multiple comparison test was performed using each 
treatment combination as an independent group. Analyses of the data from the 
autoradiographic studies were performed using a one-way ANOVA followed by a 
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Tukey-Kramer multiple comparison test. Differences were considered significant 




Antiallodynic effect of i.c.v. administered 5IA 
 In the present study, the rats presented a bilateral tactile allodynia following 
the PSL. The paw withdrawal thresholds decreased from 13.4 ± 0.9 g to 3.1 ± 0.3 g 
and from 13.4 ± 1.0 g to 4.2 ± 0.4 g in the ligated paws and the contralateral paws, 
respectively. First, we evaluated an antiallodynic effect of i.c.v. administered 5IA, 
since there has been no previous report regarding whether 5IA is able to palliate 
neuropathic pain. Figure 1A shows the antiallodynic effect observed in the ligated 
paws. Two-way ANOVA demonstrated significant main effects of treatment (F3, 90 = 
5.56, P = 0.007) and time (F4, 90 = 7.51, P < 0.001) and a significant interaction 
between treatment and time (F12, 90 = 2.85, P = 0.003). Ten nmol of 5IA 
increased %MPE values significantly at 15 min after administration (Vehicle: –3.4 ± 
2, 10 nmol: 38 ± 6). Although the effect peaked at 15 min after administration and 
decreased gradually, significant increases in %MPE values were also observed in the 
3 nmol- and 10 nmol-treated groups 30 min after administration. Similar results were 
also observed in the contralateral paws (data not shown). 
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 Next, we examined an effect of mecamylamine, a blood-brain barrier 
permeable nACh receptor antagonist, on the antiallodynic effect of 5IA. Significant 
main effects of treatment (F3, 95 = 6.75, P = 0.003) and time (F4, 95 = 5.61, P < 0.001) 
and a significant interaction between treatment and time (F12, 95 = 7.44, P < 0.001) 
were found. Mecamylamine (5 mg·kg
-1
, s.c.) blocked the effect of 5IA completely 
and the %MPE values were reduced to vehicle levels (5IA alone: 38 ± 6 and 24 ± 8, 
5IA + MEC: 3.0 ± 7 and 2.9 ± 7 at 15 and 30 min after administration, respectively) 
(Fig. 1B).  
 
Changes in the accumulation of [
125
I]5IA in vivo 
We compared [
125
I]5IA accumulation between the PSL model rats and the 
sham-operated rats using an ex vivo autoradiographic method. Representative 
autoradiograms are shown in Fig. 2A. The thalamic signals of the PSL groups were 
stronger than those of the sham-operated group, while the cortical and hippocampal 
signals were similar among the 3 groups. There was no difference between the ligated 
and contralateral sides of the PSL model rats. A significant increase (170%) in the 
accumulation of [
125
I]5IA was observed only in the thalamus in both PSL groups 
(Sham: 1.5 ± 0.15, 2 weeks: 2.6 ± 0.34, 1 month: 2.6 ± 0.08), and no detectable 
change was seen in other regions (Fig. 2B).  
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Measurement of the density of nACh receptors in vitro 
 We performed an autoradiographic saturation assay using [
125
I]5IA as a 
radioligand. The saturation binding curves are presented in Fig. 3A. Similarly to the 
ex vivo autoradiography, both PSL groups showed a significant increase in Bmax value 
that occurred in the thalamus only (Sham: 13 ± 1.9, 2 weeks: 19 ± 0.89, 1 month: 18 
± 0.81) (Fig. 3B). The percentage increase in Bmax values in the thalamus (150%) 
was similar to those observed in the ex vivo autoradiographic findings.  
 
Antiallodynic effect of intra-VPL administered 5IA 
 Based on previous reports (Derbyshire et al., 1997; Gybels, 2001; Kupers and 
Gybels, 1993), we predicted that the VPL was involved in the expression of 
antinociceptive effects and investigated the association between nACh receptors 
expressed in the VPL and the antiallodynic effect of 5IA. Figure 4A shows the 
antiallodynic effects that occurred in the ligated paws of rats that received 5IA 
intra-VPL. Two-way ANOVA demonstrated significant main effects of treatment (F4, 
115 = 3.97, P = 0.014) and time (F4, 115 = 13.6, P < 0.001) and a significant interaction 
between treatment and time (F16, 115 = 3.11, P < 0.001). There was a significant 
difference between the 50 nmol-treated group and the vehicle- or 1 nmol-treated 
groups (Vehicle: 0.82 ± 4, 1 nmol: 8.6 ± 5, 50 nmol: 30 ± 9). Although one-way 
ANOVA revealed a significant difference between the data at 30 min after 
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administration (P = 0.028), the post hoc Tukey test showed no significant difference. 
Subsequently, we injected a mixed solution of 5IA and mecamylamine (10 nmol 
each) intra-VPL and performed the von Frey filament test. Two-way ANOVA 
demonstrated significant main effects of treatment (F3, 85 = 11.34, P < 0.001) and time 
(F4, 85 = 5.22, P = 0.001) and a significant interaction between treatment and time (F12, 
85 = 4.05, P < 0.001). Mecamylamine antagonized the 5IA-induced antiallodynic 
effect completely, and furthermore, the %MPE values of mecamylamine-treated rats 
tended to decrease compared to those of the vehicle-treated rats, although the 
difference was not significant (Fig. 4B).  
 
Involvement of nACh receptors in the VPL in the antiallodynic effect induced by i.c.v. 
5IA administration 
 To explore to what extent nACh receptors in the VPL were involved in the 
antiallodynic effects arising from central nACh receptor activation, we evaluated the 
effect of intra-VPL administered mecamylamine on the antiallodynic effects 
produced by i.c.v. administered 5IA. The results from the ligated paws are illustrated 
in Figure 4C. Two-way ANOVA demonstrated significant main effects of treatment 
(F3, 105 = 7.91, P = 0.001) and time (F4, 105 = 5.65, P < 0.001) and a significant 
interaction between treatment and time (F12, 105 = 2.49, P = 0.008). The rats 
administered vehicle intra-VPL followed by 10 nmol of 5IA i.c.v. (Vehicle/5IA 
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group) demonstrated significantly elevated %MPE values at 15 and 30 min after 
administration (41 ± 20 at 15 min and 35 ± 22 at 30 min). This result was consistent 
with the antiallodynic effect produced by i.c.v. administered 5IA (Fig. 1). 
Pretreatment with intra-VPL mecamylamine (10 nmol) significantly inhibited the 
effect of i.c.v. administered 5IA (10 nmol) (10 ± 4 at 15 min and 3.6 ± 5 at 30 min, in 
the MEC/5IA group). The %MPE values for rats treated with mecamylamine alone 
(MEC/Vehicle group) also tended to decrease compared to those of the vehicle 
treated rats, although the difference was not significant. 
 
Hyperalgesic effect of intra-VPL administered mecamylamine 
To examine the effects of mecamylamine on tactile allodynia in more detail, 
we injected multiple doses of mecamylamine intra-VPL and performed the von Frey 
filament test. Data from the ligated paws are shown in Figure 5A. There was a 
significant main effect of treatment (F3, 95 = 6.77, P = 0.003) but no effect of time 
nor interaction between time and treatment. The post hoc Tukey test demonstrated a 
significant difference between vehicle-treated group and 5 nmol- or 10-nmol treated 
groups. The calculated area under the curves of each group clearly represented the 
dose-dependent hyperalgesic effects of mecamylamine (Fig. 5B). 
 
Effects of 5IA and mecamylamine on motor function 
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 We conducted an inclined plane test to evaluate the effects of 5IA and 
mecamylamine on motor functions. The maximum angle that the rats were able to 
endure before slipping down the plane was not significantly different between the 




Discussion and Conclusions 
In the present study, we examined the changes in central nACh receptor 
density in a rat model of neuropathic pain and the involvement of nACh receptors in 
antinociceptive effects in the region where changes occurred. First, we evaluated the 
antiallodynic effect of 5IA after i.c.v. administration and found that the antiallodynic 
effect was expressed in a dose-dependent manner. Because the effect was completely 
antagonized by mecamylamine, the antiallodynic effect of 5IA must occur via nACh 
receptors. No significant difference was observed between the vehicle and 5IA treated 
groups in the inclined plane test suggesting that 5IA is able to show the antiallodynic 
effect below the dose that causes adverse effects. 
We found that bilateral upregulation of thalamic nACh receptors occurred in 
the PSL model of neuropathic pain. This is the first report of upregulation of thalamic 
nACh receptors under chronic painful conditions. Because the upregulation of both 
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muscarinic and cannabinoid CB1 receptors are reported to contribute to the increased 
analgesic efficacy of each agonist (Chen and Pan, 2003; Siegling et al., 2001), 
upregulated nACh receptors may also contribute to the potentiation of antiallodynic 
effects produced by nACh receptor agonists and attenuate neuropathic pain. 
Consistent with Seltzer’s report (Seltzer et al., 1990), the unilateral PSL caused 
bilateral tactile allodynia in the present study; and thus, the upregulation must occur 
bilaterally. In the present study, we performed an autoradiographic saturation assay to 
determine the regional Bmax of nACh receptors. Since no report concerning 
autoradiographic saturation assays using [
125
I]5IA has been published, it is important 
to validate the method used. Doura et al. performed quantitative autoradiography 
using [
125
I]5IA (Doura et al., 2008). However, in their study, they incubated brain 
slices with only a single concentration of [
125
I]5IA and did not perform a saturation 
assay. Thus, a direct comparison between our present data and theirs is not possible. 
Nevertheless, the ratios of the thalamus to the striatum or the cortex of our present 
data were consistent in the data reported by Doura et al., suggesting that the method 
is valid. 
A previous PET study showed that the increase in cerebral blood flow in the 
VPL positively correlated with pain intensity, suggesting the involvement of the VPL 
in pain transmission (Derbyshire et al., 1997). Furthermore, electrical stimulation of 
the VPL has produced pain alleviation in both rat models and patients with 
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neuropathic pain (Gybels, 2001; Kupers and Gybels, 1993). These findings suggest 
that the VPL is involved in the expression of antinociceptive effects. Indeed, we 
demonstrated that 5IA administered locally into the VPL significantly and 
dose-dependently reversed tactile allodynia. This effect was antagonized by 
coadministered mecamylamine. Since no significant difference was observed 
between the vehicle and 5IA treated groups in the results of an inclined plane test, the 
changes in %MPE values observed in the 5IA treated groups were considered to 
reflect the analgesic effect, not motor dysfunction. These findings suggest that the 
nACh receptors expressed in the VPL were involved in the antiallodynic effect that 
occurred after nACh receptor agonist administration. This was consistent with the 
finding that blockade of nACh receptors in the VPL caused a decrease in the 
antiallodynic effect of i.c.v.-administered 5IA. Moreover, intra-VPL administered 
mecamylamine induced significant decreases in %MPE values. Mecamylamine is not 
an inverse agonist, but a non-competitive antagonist (Jensen et al., 2005). Thus, 
during neuropathic pain, an intrinsic antiallodynic mechanism by which ACh 
activated nACh receptors expressed in the VPL may be present, and antagonism by 
mecamylamine cause a hyperalgesic effect. That is to say, the nACh receptors 
expressed in the VPL may participate in antiallodynic effects produced not only by 
exogenous but also endogenous agonists. 
The present findings do not negate the involvement of nACh receptors in 
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antiallodynic effects outside of the VPL. Previous pharmacological studies reported 
that the central sites involved in nACh receptor-mediated antinociception were the 
NRM and the PPTg. Iwamoto et al. reported that the antinociception produced by 
nicotinic stimulation of the PPTg or the NRM depended upon muscarinic cholinergic, 
serotonergic, and adrenergic systems at the level of the lumbar spinal cord (Iwamoto 
and Marion, 1993). Curzon et al. showed that microinjection of nACh receptor 
agonists (epibatidine and A-85380) into the NRM produced antinociception against 
heat stimuli, and these effects were prevented by coadministration of mecamylamine 
into the NRM (Curzon et al., 1998). Indeed, we demonstrated that VPL blockade by 
mecamylamine before i.c.v. administration of 5IA decreased the antiallodynic effect 
by up to approximately 70%, not 100%. Thus, the remainder of the antiallodynic 
effect is possibly caused by the binding of 5IA to the NRM and/or the PPTg. 
Recently, Mogg et al. have reported that 5IA can functionally activate the 
α4β2-nACh and α6β2-nACh receptors (Mogg et al., 2004). On the other hand, Perry 
et al. reported that the nACh receptors expressed in the thalamus were mainly of the 
α4β2 (Perry et al., 2002) and that the α6 subunit was present in less than 4% of the 
thalamic nACh receptors (Perry et al., 2007). Therefore, the antiallodynic effect is 
probably mediated via the α4β2-nACh receptors, at least when 5IA was administered 
into the VPL. Whereas many results have shown that α4 subunit-containing nACh 
receptors play an important role in nACh receptor-mediated antinociception (Bitner et 
 24 
al., 1998; Bitner et al., 2000; Marubio et al., 1999), the contribution of the 
α6β2-nACh receptors to the antinociceptive effect is unknown. Since A-186253 has 
recently been developed as a specific antagonist of the α4β2-nACh receptors (Itier et 
al., 2004), it may be possible to investigate α6β2-nACh receptor-mediated 
antinociception using both 5IA and A-186253. 
In summary, we have demonstrated for the first time that upregulation of 
thalamic nACh receptors occurs under chronic painful conditions. Moreover, we 
revealed that intra-VPL administration of 5IA attenuates tactile allodynia in a 
dose-dependent manner. This effect was completely antagonized by coadministered 
mecamylamine. The blockade of nACh receptors in the VPL by mecamylamine 
caused a decrease in the antiallodynic effect of i.c.v.-administered 5IA. These 
findings indicate that the nACh receptors expressed in the VPL are a potential site of 
the antinociceptive action produced by 5IA. Furthermore, intra-VPL administered 
mecamylamine induced a hyperalgesic effect. This effect is likely to be responsible 
for the mecamylamine antagonism of the intrinsic antiallodynic mechanism induced 
by endogenous acetylcholine. These findings suggest that the nACh receptors 
expressed in the VPL play an important role in the antiallodynic effects produced by 
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Table 1. Effects of 5IA on motor functions  
 Time after administration 




98 ± 1 
 
102 ± 4 
 
98 ± 2 
 
92 ± 3 
 





93 ± 2 
 
99 ± 3 
100 ± 4 
97 ± 3 
 
99 ± 2 
97 ± 2 
88 ± 4 
 
97 ± 4 
99 ± 2 
96 ± 3 
 
100 ± 2 
97 ± 1 
93 ± 1 
 
97 ± 3 
102 ± 2 
Data are expressed as a percentage of the control level, which was determined before 
drug administration in each animal, and represent the mean ± SEM of five to six 
animals per group. No significant difference was observed between the two groups 












(A) Effect of i.c.v. administered 5IA on neuropathic tactile allodynia. Data are 
presented as a percentage of the maximum possible effect. Each point represents the 
mean ± SEM of the ligated paws of five to six animals per group. *p < 0.05 vs. 
vehicle at the same time point. (B) Effect of mecamylamine (MEC, 5 mg·kg
-1
, s.c., 30 
min prior) on the antiallodynic effect induced by 5IA (i.c.v.). Data are presented as a 
percentage of the maximum possible effect. Each point represents the mean ± SEM of 
the ligated paws of five to six animals per group. **p < 0.01 vs. vehicle, #p < 0.05, 








(A) Representative autoradiograms of sham-operated and PSL rats. (B) Changes in 
the regional accumulation of [
125I]5IA in Seltzer’s PSL model of neuropathic pain. A 
significant increase was observed only in the thalamus, and no detectable change 
occurred in other regions. Each column represents the mean ± SEM of four to seven 
animals per group. *p < 0.05 vs. sham. Abbreviations: Frn: frontal cortex; Str: 
striatum; Hip: hippocampus; Th: thalamus; PPTg: pedunculopontine tegmental 








(A) Saturation curves of [
125
I]5IA binding to sham-operated and PSL rat thalamus. 
Each point represents the mean ± SEM of five to seven animals per group. The Bmax 
values estimated by nonlinear regression analysis of these mean data were 12.5, 19.9, 
and 21.2 fmol/mg protein in sham-operated, 2-week post-PSL, and 1-month post-PSL 
group, respectively. (B) Changes in nACh receptor density in Seltzer’s PSL model of 
neuropathic pain. A significant increase was observed only in the thalamus, and no 
detectable change occurred in other regions. Each column represents the mean ± 
SEM of five to seven animals per group. *p < 0.05, **p < 0.01 vs. sham. 
Abbreviations: Frn: frontal cortex; Str: striatum; Hip: hippocampus; Th: thalamus; 
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PPTg: pedunculopontine tegmental nucleus; NRM: nucleus raphe magnus; LC: locus 
coeruleus; Cer: cerebellum. 
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(A) Effect of intra-VPL administered 5IA on neuropathic tactile allodynia. Data are 
presented as a percentage of the maximum possible effect. Each point represents the 
mean ± SEM of the ligated paws of five to six animals per group. *p < 0.05, **p < 
 39 
0.01 vs. vehicle, and #p < 0.05 vs. 1 nmol of 5IA at the same time point. (B) Effect of 
mecamylamine (MEC, 10 nmol/0.5 μL) administered concurrently with 5IA in an 
intra-VPL manner on the antiallodynic effect produced by 5IA (10 nmol/0.5 μL, 
intra-VPL). Data are presented as a percentage of the maximum possible effect. Each 
point represents the mean ± SEM of the ligated paws of five to six animals per group. 
*p < 0.05, **p < 0.01 vs. vehicle, #p < 0.05, ##p < 0.01 vs. MEC alone, and †p < 
0.05, ††p < 0.01 vs. 5IA alone at the same time point. (C) Effect of mecamylamine 
(MEC, 10 nmol/0.5 μL, intra-VPL, 5 min prior) on the antiallodynic effect produced 
by 5IA (10 nmol/5 μL, i.c.v.). Data are presented as a percentage of the maximum 
possible effect. Each point represents the mean ± SEM of the ligated paws of four to 
seven animals per group. *p < 0.05, **p < 0.01 vs. vehicle/vehicle, #p < 0.05, ##p < 
0.01 vs. MEC/vehicle, and †p < 0.05 vs. vehicle/5IA at the same time point. 
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(A) Effect of intra-VPL administered mecamylamine on neuropathic tactile allodynia. 
Data are presented as a percentage of the maximum possible effect. Each point 
represents the mean ± SEM of the ligated paws of five to six animals per group. *p < 
0.05 vs. vehicle at the same time point. (B) Dose-response curve of 
mecamylamine-induced hyperalgesia. The open symbol represents the AUC of the 
vehicle-treated group, and the closed symbols represent that of each concentration of 
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